재정 지원 요구사항을 통해 공개된 자료 - Bahar Saberzadeh Ardestani자세히 알아보기
제공된 곳이 있음: 11
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ...
The Lancet 400 (10352), 563-591, 2022
재정 지원 요구사항 정책: Bill & Melinda Gates Foundation, US National Institutes of Health, National …
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
GBDCC Collaborators
the lancet gastroenterology and hepatology, 2022
재정 지원 요구사항 정책: Bill & Melinda Gates Foundation, US National Institutes of Health, National …
Type 1 diabetes mellitus: cellular and molecular pathophysiology at a glance
B Saberzadeh-Ardestani, R Karamzadeh, M Basiri, E Hajizadeh-Saffar, ...
Cell Journal (Yakhteh) 20 (3), 294, 2018
재정 지원 요구사항 정책: US National Science Foundation
Association between survival and metastatic site in mismatch repair–deficient metastatic colorectal cancer treated with first-line pembrolizumab
B Saberzadeh-Ardestani, JC Jones, JM Hubbard, RR McWilliams, ...
JAMA Network Open 6 (2), e230400-e230400, 2023
재정 지원 요구사항 정책: US National Institutes of Health
Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147)[Alliance]
B Saberzadeh-Ardestani, NR Foster, HE Lee, Q Shi, SR Alberts, ...
Annals of Oncology 33 (11), 1159-1167, 2022
재정 지원 요구사항 정책: US National Institutes of Health
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
JV Lazarus, H Han, HE Mark, SA Alqahtani, JM Schattenberg, JB Soriano, ...
Hepatology 78 (3), 911-928, 2023
재정 지원 요구사항 정책: Bill & Melinda Gates Foundation, UK Medical Research Council, Government of …
Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors
C Gallois, M Landi, J Taieb, M Sroussi, B Saberzadeh-Ardestani, ...
Clinical Cancer Research 29 (18), 3771-3778, 2023
재정 지원 요구사항 정책: National Institute of Health and Medical Research, France
Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
B Saberzadeh-Ardestani, RP Graham, S McMahon, E Ahanonu, Q Shi, ...
Clinical Cancer Research 29 (20), 4268-4277, 2023
재정 지원 요구사항 정책: US National Institutes of Health
Outcomes of COVID-19 in patients with inflammatory bowel disease: comparison with household members and the role of IBD medications
AR Sima, B Saberzadeh-Ardestani, H Vahedi, H Fakheri, ...
Archives of Iranian Medicine 25 (1), 17-25, 2022
재정 지원 요구사항 정책: US National Institutes of Health
Comparison of Disease Phenotype and Course among Elderly-and Early-Onset Inflammatory Bowel Diseases in the Middle East
H Vosoghinia, B Saberzadeh-Ardestani, A Anushiravani, ...
Archives of Iranian Medicine 26 (9), 481, 2023
재정 지원 요구사항 정책: US National Institutes of Health
569P Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
FA Sinicrope, G Nelson, BS Ardestani, G Park, Y Lim, D Yan, ...
Annals of Oncology 34, S420, 2023
재정 지원 요구사항 정책: US National Institutes of Health
발행인 및 자금 지원 정보는 컴퓨터 프로그램에서 자동으로 결정됩니다.